The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial
Updated 05 August 2020
THE COVID-19 PANDEMIC: AN UPDATE ON HOW IT IS AFFECTING H4RT
The study sponsor North Bristol Trust have agreed to RESTART the H4RT study on 4th August 2020. Please contact the H4RT study team (firstname.lastname@example.org) to restart at your site.
Our research aims to establish the effectiveness of haemodialysis versus haemodiafiltration in the treatment of kidney disease.
End stage kidney disease affects around 65,000 people in the UK. Almost half of these people will have blood cleaning treatment known as haemodialysis at a hospital.
The addition of filtration (the removal and replacement of fluid) to regular haemodialysis is known as haemodiafiltration. This does not change the dialysis procedure as far as the patient is concerned - it is still 4 hours 3 times a week, it just requires change in equipment and nurse practice.
By removing toxins more effectively, haemodiafiltration may improve survival, infection rates and quality of life of patients.
H4RT is a non-blinded Randomised Controlled Trial comparing the clinical and cost-effectiveness of high-volume HDF compared with high-flux HD in the treatment of end stage kidney disease.
Recruitment for the H4RT trial began in November 2017 and will run until 31 March 2021.
For further information about this research, please contact:
Dr Fergus Caskey- Trial Chief Investigator, Consultant Senior Lecturer (University of Bristol) and Honorary Consultant Nephrologist (North Bristol NHS Trust)
Dr Sunita Procter - Trial Manager
The study is funded by NIHR Health Technology Assessment.